These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6686773)

  • 1. Effect of penbutolol on lidocaine kinetics.
    Ochs HR; Skanderra D; Abernethy DR; Greenblatt DJ
    Arzneimittelforschung; 1983; 33(12):1680-1. PubMed ID: 6686773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding.
    Aguirre C; Trocóniz IF; Valdivieso A; Jiménez RM; González JP; Calvo R; Rodríguez-Sasiaín JM
    Res Commun Mol Pathol Pharmacol; 1996 Apr; 92(1):53-72. PubMed ID: 8733828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modification of myocardial function parameters by L- and D-penbutolol--an echocardiography, placebo-controlled double-blind study].
    Grube E; Herzog H; Lüderitz B
    Z Kardiol; 1985 Feb; 74(2):99-105. PubMed ID: 3993154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.
    Bax ND; Jones RW; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 May; 19(5):593-6. PubMed ID: 4005101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of piretanide tablets, penbutolol tablets and the fixed combination of both drugs in healthy male subjects after a single oral dose.
    Müller F; Meyer B; Grigoleit HG
    Int J Clin Pharmacol Res; 1987; 7(6):469-75. PubMed ID: 3440637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.
    Ochs HR; Hajdú P; Greenblatt DJ
    Klin Wochenschr; 1986 Jul; 64(14):636-41. PubMed ID: 3762014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical electrophysiological properties of penbutolol: a non-selective beta-blocking agent.
    von Leitner ER; Biamino G
    Eur J Cardiol; 1980; 12(2):121-8. PubMed ID: 7439238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of penbutolol on glomerular filtration.
    Meyer BH; Müller FO; Lötter MG; Iturralde MP; Grigoleit HG
    S Afr Med J; 1981 Aug; 60(6):243-4. PubMed ID: 7020108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.
    Abernethy DR; Greenblatt DJ; Shader RI
    J Pharmacol Exp Ther; 1984 Jun; 229(3):702-5. PubMed ID: 6726654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lidocaine pharmacokinetics in children during general anesthesia.
    Finholt DA; Stirt JA; DiFazio CA; Moscicki JC
    Anesth Analg; 1986 Mar; 65(3):279-82. PubMed ID: 3954094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol.
    Vedin JA; Wilhelmsson C; Maass L; Peterson LE
    Eur J Clin Pharmacol; 1983; 25(4):529-34. PubMed ID: 6653649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.
    Wellstein A; Palm D
    Eur J Clin Pharmacol; 1985; 29(3):293-300. PubMed ID: 3000796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.
    Spahn H; Kirch W; Hajdu P; Mutschler E; Ohnhaus EE
    Eur J Clin Pharmacol; 1986; 29(5):555-60. PubMed ID: 3956561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in penbutolol central response as a cause of changes in its serum protein binding.
    Martínez Jordá R; Aguirre C; Calvo R; Rodríguez-Sasiaín JM; Erill S
    J Pharm Pharmacol; 1990 Mar; 42(3):164-6. PubMed ID: 1974610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic sympathomimetic activity of penbutolol.
    Nyberg G; Wilhelmsson C; Vedin A
    Eur J Clin Pharmacol; 1979; 16(6):381-6. PubMed ID: 43255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age, gender, and obesity on midazolam kinetics.
    Greenblatt DJ; Abernethy DR; Locniskar A; Harmatz JS; Limjuco RA; Shader RI
    Anesthesiology; 1984 Jul; 61(1):27-35. PubMed ID: 6742481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penbutolol: a new beta-adrenergic blocking agent.
    Schlanz KD; Thomas RL
    DICP; 1990 Apr; 24(4):403-8. PubMed ID: 2183495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.
    Silke B; Verma SP; Hussain M; Nelson GI; Okoli RC; Taylor SH
    Br J Clin Pharmacol; 1983 Nov; 16(5):529-35. PubMed ID: 6315039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.